Skip to main content
NVDA-2.58%AAPL+2.70%GOOGL+0.37%MSFT-0.15%AMZN-0.17%TSM-1.31%SPCX+0.82%AVGO-0.52%META-1.02%TSLA-0.63%SKHY-4.08%MU-4.41%BRK-B-0.24%LLY+0.15%JPM-0.63%WMT+0.08%AMD-3.01%V-0.18%XOM+0.68%ASMLa-1.66%JNJ-0.01%INTC-4.65%MA-0.56%0700.HK-1.94%1398.HK+0.79%ORCL-4.08%ABBV+0.89%BAC-0.49%CSCO-1.24%CVX-0.30%COST-0.21%KO+0.67%LRCX-4.89%CAT-1.36%AP2d-1.55%0005.HK-0.78%AMAT-2.37%UNH-0.63%HSBA.L-1.30%DELL-4.07%PG+0.35%MS-1.27%GE-0.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.09%HD-1.76%0939.HK+1.66%GS-1.31%NZDJPY-2.62%AUDJPY-1.83%CHFJPY-1.60%NZDCAD-1.48%EURNZD+1.47%NZDUSD-1.44%GBPNZD+1.41%GBPJPY-1.23%USDJPY-1.22%EURJPY-1.21%CADJPY-1.17%NZDCHF-1.06%USDZAR+1.03%USDSEK+0.91%USDNOK+0.90%EURZAR+0.86%AUDNZD+0.83%GBPZAR+0.77%EURSEK+0.74%EURNOK+0.74%AUDCAD-0.69%USDTHB+0.66%AUDDKK-0.66%EURAUD+0.63%AUDUSD-0.62%GBPAUD+0.58%CHFSEK+0.56%AUDSGD-0.56%CHFNOK+0.55%USDMXN+0.51%NZDSGD-0.45%USDPLN+0.43%CADCHF+0.42%GBPTRY+0.41%USDCHF+0.40%EURCHF+0.40%NOKJPY-0.38%GBPCHF+0.36%GBPHKD+0.32%GBPMXN-0.28%USDSGD+0.27%EURPLN+0.27%SGDJPY+0.25%AUDCHF-0.23%NZDMXN-0.23%EURHKD-0.17%USDDKK+0.16%USDILS+0.16%USDTRY+0.11%EURSGD+0.11%USDCNH+0.10%PLNJPY+0.09%GBPCAD-0.08%CHFSGD-0.08%AUDNOK+0.07%EURCZK-0.05%EURGBP+0.05%EURCNH-0.04%USDCOP-0.04%EURCAD-0.04%USDCAD-0.03%GBPUSD-0.02%USDHKD+0.02%GBPSGD+0.01%EURUSD0.00%EURDKK0.00%XPTUSD-6.02%UKOIL+5.13%XAGUSD-5.11%GAGUSD-5.11%USOIL+4.96%HG1-4.92%XNGUSD+1.70%GAUUSD-1.50%XAUUSD-1.50%SUGAR0.00%S10.00%COFFEE0.00%BTCUSD-1.57%ETHUSD-0.44%USDTUSD-0.03%XRPUSD-3.32%SOLUSD-2.20%TRXUSDT+0.15%ZECUSDT-9.76%DOGEUSD-3.10%XMRUSDT-0.40%LINKUSD-1.59%XLMUSD-1.74%BCHUSDT-10.46%LTCUSD-1.99%UNIUSD-1.71%TONUSD+24.88%HBARUSDT-2.45%SUIUSD-4.49%TAOUSDT-5.69%AAVEUSD-2.65%DOTUSDT-2.01%ICPUSDT-1.73%ONDOUSDT-3.56%WLDUSDT-3.63%ATOMUSDT-3.46%ARBUSDT-0.16%JUPUSDT-3.82%INJUSDT-2.88%STXUSDT-4.16%FETUSDT-3.62%TIAUSDT-1.39%PYTHUSDT-1.49%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-3.63%WIFUSDT-5.87%OPUSDT-4.00%POLUSDT-4.56%IOTAUSDT-3.83%AXSUSDT-2.47%FARTCOINUSDT-4.35%EOSUSDT-2.91%DYDXUSDT-2.55%ORDIUSDT-0.97%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.58%AAPL+2.70%GOOGL+0.37%MSFT-0.15%AMZN-0.17%TSM-1.31%SPCX+0.82%AVGO-0.52%META-1.02%TSLA-0.63%SKHY-4.08%MU-4.41%BRK-B-0.24%LLY+0.15%JPM-0.63%WMT+0.08%AMD-3.01%V-0.18%XOM+0.68%ASMLa-1.66%JNJ-0.01%INTC-4.65%MA-0.56%0700.HK-1.94%1398.HK+0.79%ORCL-4.08%ABBV+0.89%BAC-0.49%CSCO-1.24%CVX-0.30%COST-0.21%KO+0.67%LRCX-4.89%CAT-1.36%AP2d-1.55%0005.HK-0.78%AMAT-2.37%UNH-0.63%HSBA.L-1.30%DELL-4.07%PG+0.35%MS-1.27%GE-0.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.09%HD-1.76%0939.HK+1.66%GS-1.31%NZDJPY-2.62%AUDJPY-1.83%CHFJPY-1.60%NZDCAD-1.48%EURNZD+1.47%NZDUSD-1.44%GBPNZD+1.41%GBPJPY-1.23%USDJPY-1.22%EURJPY-1.21%CADJPY-1.17%NZDCHF-1.06%USDZAR+1.03%USDSEK+0.91%USDNOK+0.90%EURZAR+0.86%AUDNZD+0.83%GBPZAR+0.77%EURSEK+0.74%EURNOK+0.74%AUDCAD-0.69%USDTHB+0.66%AUDDKK-0.66%EURAUD+0.63%AUDUSD-0.62%GBPAUD+0.58%CHFSEK+0.56%AUDSGD-0.56%CHFNOK+0.55%USDMXN+0.51%NZDSGD-0.45%USDPLN+0.43%CADCHF+0.42%GBPTRY+0.41%USDCHF+0.40%EURCHF+0.40%NOKJPY-0.38%GBPCHF+0.36%GBPHKD+0.32%GBPMXN-0.28%USDSGD+0.27%EURPLN+0.27%SGDJPY+0.25%AUDCHF-0.23%NZDMXN-0.23%EURHKD-0.17%USDDKK+0.16%USDILS+0.16%USDTRY+0.11%EURSGD+0.11%USDCNH+0.10%PLNJPY+0.09%GBPCAD-0.08%CHFSGD-0.08%AUDNOK+0.07%EURCZK-0.05%EURGBP+0.05%EURCNH-0.04%USDCOP-0.04%EURCAD-0.04%USDCAD-0.03%GBPUSD-0.02%USDHKD+0.02%GBPSGD+0.01%EURUSD0.00%EURDKK0.00%XPTUSD-6.02%UKOIL+5.13%XAGUSD-5.11%GAGUSD-5.11%USOIL+4.96%HG1-4.92%XNGUSD+1.70%GAUUSD-1.50%XAUUSD-1.50%SUGAR0.00%S10.00%COFFEE0.00%BTCUSD-1.57%ETHUSD-0.44%USDTUSD-0.03%XRPUSD-3.32%SOLUSD-2.20%TRXUSDT+0.15%ZECUSDT-9.76%DOGEUSD-3.10%XMRUSDT-0.40%LINKUSD-1.59%XLMUSD-1.74%BCHUSDT-10.46%LTCUSD-1.99%UNIUSD-1.71%TONUSD+24.88%HBARUSDT-2.45%SUIUSD-4.49%TAOUSDT-5.69%AAVEUSD-2.65%DOTUSDT-2.01%ICPUSDT-1.73%ONDOUSDT-3.56%WLDUSDT-3.63%ATOMUSDT-3.46%ARBUSDT-0.16%JUPUSDT-3.82%INJUSDT-2.88%STXUSDT-4.16%FETUSDT-3.62%TIAUSDT-1.39%PYTHUSDT-1.49%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-3.63%WIFUSDT-5.87%OPUSDT-4.00%POLUSDT-4.56%IOTAUSDT-3.83%AXSUSDT-2.47%FARTCOINUSDT-4.35%EOSUSDT-2.91%DYDXUSDT-2.55%ORDIUSDT-0.97%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%
TP

Tarsus Pharmaceuticals, Inc. (TARS)

NASDAQ • Healthcare

$82.77
-$4.45 (-5.1%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$86.31
Previous Close$82.77
Day Range$82.67 - $87.31
Avg. Volume (3M)808.4K
Market Cap$3.5B
52 Week Range
$48.2$91.53
Next EarningsIn 54 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$173.9M100%
Gross Profitminus cost of goods$161.7M93%

In plain terms: out of every $100 in revenue, Tarsus Pharmaceuticals, Inc. currently loses $11.

Fundamentals & Financials

Revenue (TTM)
$606.3M
Net Income (TTM)
-$46.4M
EPS (TTM)
-$1.09
ROA (TTM)
-7.6%
Current Ratio
3.2

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-94.2%Q1 2026-$0.2
+60.2%Q2 2026-$0.16
-124.2%Q3 2026-$0.43
Next

Nov 3

in 54 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a biotechnology company developing lotilaner-based medicines, centered mainly on ocular disease while extending into dermatology and infectious-disease uses. In FY2025, it recorded $451.4 million in revenue. Its work is organized around investigational therapies for blepharitis, rosacea, Lyme disease prevention, and community-level malaria reduction.

Name
Tarsus Pharmaceuticals, Inc.
CEO
Bobak R. Azamian
Website
www.tarsusrx.com
Industry
Healthcare
Year Founded
2016
Employees
370

Today's Snapshot

AI-generated

So far today, TARS is trading 0.7% lower at 82.21, while its sector was flat.

Trading Volume

Below 10d avg (957.4K)

168K

vs S&P 500 Today

Moderate Underperformance

-0.12%

Updated: September 10, 2026 at 17:00 UTC

Technical Indicators

6 Buy2 Neutral0 Sell
TARS exhibits a robust bullish structure with multiple confirmations from trend, momentum and volume measures. The stock trades above its key short-, medium- and long-term moving averages and the ADX shows a strong trending environment, while MACD and a positive momentum reading reinforce upside internal strength. On-balance volume is supportive, indicating participation behind the move, and volatility is moderate so moves are orderly. The intraday VWAP sits close to price but does not negate the broader technical alignment. Technical takeaway: strong buy affirmed by trend strength, momentum and supportive volume.
All signals
  • EMA (5 indicators)$67.78 - $80.88
    Buy
  • RSI (14)63.88
    Neutral
  • Stochastic %K (14, 3, 3)66.56
    Neutral
  • MACD Level (12, 26)5.15
    Buy

Peers & Related Assets

SRRKScholar Rock Holding Corporation
$54.62-4.9%
CGONCG Oncology Inc.
$71.96-2.0%
TVTXTravere Therapeutics, Inc.
$66.22+0.2%
CELCCelcuity Inc.
$90.08-3.2%
ADPTAdaptive Biotechnologies Corporation
$24.42+0.3%
ARQTArcutis Biotherapeutics, Inc.
$23.84-2.3%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.